Conversation with The Cancer Letter Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out July 25, 2025Vol.51 No.29By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg
Cancer Policy FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts July 25, 2025Vol.51 No.29By Jacquelyn Cobb
Clinical Roundup Enrollment begins in NCI’s Vanguard study focused on defining benefits of MCD tests July 18, 2025Vol.51 No.28
Cancer Policy Supreme Court lifts lower-court freeze on RIFs July 11, 2025Vol.51 No.27By Jacquelyn Cobb
Funding Opportunities NCI, SITC immunotherapy fellowship calls for applications July 11, 2025Vol.51 No.27
FreeGuest Editorial As cancer scientists, we must change how we engage with the public on the impact of NIH cutsWhat the scientific method obscures July 03, 2025Vol.51 No.26By George J. Weiner and Elizabeth M. Jaffee
In Brief RWJBarnabas Health, Rutgers Cancer Institute welcomes first patients June 27, 2025Vol.51 No.25
PodcastThe Directors The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woesDirectors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” June 13, 2025Vol.51 No.23By Paul Goldberg
Regulatory News In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.” June 13, 2025Vol.51 No.23By Jacquelyn Cobb
Cancer Policy George Sigounas named the first-ever chief science advisor at NCI June 06, 2025Vol.51 No.22By Paul Goldberg
